Tahir Amin, DipLP, co-founder and director of intellectual property of Initiative for Medicines, Access, and Knowledge, discusses his organization's ongoing work in challenging drug patents.
Transcript:
What are some of the cases you’re working on now?
So one of the major cases we’re working on is Sofosbuvir, branded as Sovaldi. It’s a hepatitis C drug, and currently we filed 10 IPRs last year in the United States [Patent Trial and Appeal Board, PTAB]. Currently, we’re waiting to hear whether those will be instituted, and by instituted, I mean whether the PTAB will take those cases on and will go into trial.
We have a number of cases going on in India involving hepatitis C drugs, and in China we already had some successful decisions.
The importance of these cases is to show that a lot of people are still not getting these new, direct-acting anti-viral hepatitis C drugs, and we feel that our work is to try and create an opportunity for people lacking access to get them.
Also, in the United States, a lot of people living with hepatitis C are not getting the treatment that they need, and I hope the cases we have brought will leverage some opportunities to try and get these drugs at more affordable prices, because only 1% of the number of Americans that need the drug are getting it at the moment.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
How Vertical Integration Drives Innovation and Access in Biosimilars
December 27th 2024Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while emphasizing the value of collaboration, quality control, and value-based contracts for sustainable health care delivery.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.